Close Menu

NEW YORK – Ortho Clinical Diagnostics said today that the US Food and Drug Administration has cleared its Ortho Sera suite of reagents that enable extended antigen phenotyping.

The product was cleared for use with the Ortho Vision analyzer.

Ortho said that the reagents cover more than 99 percent of the most commonly tested blood group antigens, providing support for patients with unexpected antibodies. The reagents' antisera additive approach allows extended phenotyping to be personalized according to patient needs, reducing waste, and enhancing efficiency, the firm said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Sponsored by

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.